Quantitative mathematical modeling of clinical brain metastasis dynamics in non-small cell lung cancer.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
10 09 2019
Historique:
received: 16 04 2019
accepted: 23 08 2019
entrez: 12 9 2019
pubmed: 12 9 2019
medline: 5 11 2020
Statut: epublish

Résumé

Brain metastases (BMs) are associated with poor prognosis in non-small cell lung cancer (NSCLC), but are only visible when large enough. Therapeutic decisions such as whole brain radiation therapy would benefit from patient-specific predictions of radiologically undetectable BMs. Here, we propose a mathematical modeling approach and use it to analyze clinical data of BM from NSCLC. Primary tumor growth was best described by a gompertzian model for the pre-diagnosis history, followed by a tumor growth inhibition model during treatment. Growth parameters were estimated only from the size at diagnosis and histology, but predicted plausible individual estimates of the tumor age (2.1-5.3 years). Multiple metastatic models were further assessed from fitting either literature data of BM probability (n = 183 patients) or longitudinal measurements of visible BMs in two patients. Among the tested models, the one featuring dormancy was best able to describe the data. It predicted latency phases of 4.4-5.7 months and onset of BMs 14-19 months before diagnosis. This quantitative model paves the way for a computational tool of potential help during therapeutic management.

Identifiants

pubmed: 31506498
doi: 10.1038/s41598-019-49407-3
pii: 10.1038/s41598-019-49407-3
pmc: PMC6736889
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

13018

Références

J Chronic Dis. 1968 Dec;21(7):493-506
pubmed: 5703836
Nat Med. 2008 Aug;14(8):822-7
pubmed: 18641660
Cancer Res. 2016 Sep 1;76(17):4931-40
pubmed: 27302167
Semin Cancer Biol. 2015 Dec;35:53-61
pubmed: 26361213
J Theor Biol. 2000 Mar 21;203(2):177-86
pubmed: 10704301
Nat Med. 1995 Feb;1(2):149-53
pubmed: 7585012
Cancer Res. 2017 Sep 15;77(18):5183-5193
pubmed: 28729417
Nat Rev Cancer. 2002 Aug;2(8):563-72
pubmed: 12154349
Methods Mol Biol. 2018;1711:193-224
pubmed: 29344891
Bull Cancer. 2013 Jan 1;100(1):51-6
pubmed: 23376539
C R Seances Acad Sci III. 1982 Jan 4;294(1):15-8
pubmed: 6804023
Cancer. 2009 Jul 1;115(13):2930-8
pubmed: 19441110
Nat Med. 2010 Jan;16(1):116-22
pubmed: 20023634
Oncotarget. 2016 Aug 30;7(35):56998-57010
pubmed: 27486770
Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):131-141
pubmed: 28586952
Cancer Res. 1988 Dec 15;48(24 Pt 1):7067-71
pubmed: 3191483
Cancer Res. 2016 Feb 1;76(3):535-47
pubmed: 26511632
Breast Cancer Res Treat. 1997 Sep;45(2):193-202
pubmed: 9342444
Nat Rev Cancer. 2009 Apr;9(4):302-12
pubmed: 19308069
Neuro Oncol. 2017 Feb 1;19(2):162-174
pubmed: 28391295
J Thorac Oncol. 2016 Oct;11(10):1718-28
pubmed: 27237825
Nat Rev Clin Oncol. 2016 Apr;13(4):242-54
pubmed: 26598946
Science. 2018 Sep 7;361(6406):1033-1037
pubmed: 30190408
Cancer Res. 1972 Feb;32(2):367-73
pubmed: 5058192
Nature. 2015 Apr 16;520(7547):353-357
pubmed: 25830880
Br J Cancer. 1965 Jun;19:278-91
pubmed: 14316202
Math Biosci. 2009 Mar;218(1):1-14
pubmed: 19121638
PLoS Comput Biol. 2014 Aug 28;10(8):e1003800
pubmed: 25167199
Anticancer Res. 2013 May;33(5):2159-67
pubmed: 23645770
J Clin Oncol. 2009 Sep 1;27(25):4103-8
pubmed: 19636014
Am J Roentgenol Radium Ther Nucl Med. 1956 Nov;76(5):988-1000
pubmed: 13362715
Nat Med. 1998 Sep;4(9):984
pubmed: 9734370
Cell. 2012 Jan 20;148(1-2):362-75
pubmed: 22265421
PLoS Comput Biol. 2015 Nov 23;11(11):e1004626
pubmed: 26599078
PLoS One. 2012;7(4):e34637
pubmed: 22558094
Clin Neurol Neurosurg. 2017 Sep;160:96-100
pubmed: 28704781
Nat Rev Cancer. 2010 Mar;10(3):221-30
pubmed: 20179714
Nat Rev Cancer. 2015 Dec;15(12):730-45
pubmed: 26597528
Biometrics. 1976 Sep;32(3):535-50
pubmed: 963169
Int J Mol Sci. 2016 Dec 18;17(12):
pubmed: 27999344
Cancer Res. 2014 Nov 15;74(22):6397-407
pubmed: 25217520
CPT Pharmacometrics Syst Pharmacol. 2018 Jan;7(1):42-50
pubmed: 29218795
Br J Cancer. 1985 Oct;52(4):515-24
pubmed: 4063132
Nat Rev Cancer. 2009 Apr;9(4):274-84
pubmed: 19308067
PLoS One. 2014 Jan 21;9(1):e84249
pubmed: 24465399
Nat Commun. 2014 Jun 03;5:4006
pubmed: 24892406
J Neurooncol. 2019 Sep;144(2):351-358
pubmed: 31302830
Cancer Res. 2016 Mar 1;76(5):1009-18
pubmed: 26833128
Lancet. 2016 Oct 22;388(10055):2004-2014
pubmed: 27604504
J Thorac Oncol. 2008 Jul;3(7):781-92
pubmed: 18594326
Ann Surg. 1971 Aug;174(2):161-6
pubmed: 5560840
J Clin Oncol. 2004 Jul 15;22(14):2865-72
pubmed: 15254054
Science. 2018 Sep 28;361(6409):1314-1315
pubmed: 30262486
Radiat Oncol. 2012 May 28;7:77
pubmed: 22640600
J Theor Biol. 2006 Dec 7;243(3):407-17
pubmed: 16930629
Oncology (Williston Park). 2011 Jan;25(1):38-43, 46
pubmed: 21361242
J Surg Oncol. 1997 Aug;65(4):284-97
pubmed: 9274795
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
J Surg Oncol. 1995 Oct;60(2):137-46
pubmed: 7564383
Radiology. 2007 Mar;242(3):882-8
pubmed: 17229875
Bull Cancer. 2013 Mar;100(3):303-8
pubmed: 23518334
J Mol Med (Berl). 2015 Nov;93(11):1213-20
pubmed: 26489608
Lancet. 2016 Oct 22;388(10055):1960-1962
pubmed: 27604505
Cell. 2006 Nov 17;127(4):679-95
pubmed: 17110329
CNS Oncol. 2014 May;3(3):219-30
pubmed: 25055130
Nat Med. 2006 Aug;12(8):875-8
pubmed: 16892025
J Theor Biol. 2006 Jun 21;240(4):521-30
pubmed: 16343545
Radiother Oncol. 2017 May;123(2):195-202
pubmed: 28363487
Int J Radiat Oncol Biol Phys. 2019 Mar 1;103(3):631-637
pubmed: 30395905

Auteurs

M Bilous (M)

MONC team, Inria Bordeaux Sud-Ouest, Talence, France.
Institut de Mathématiques de Bordeaux, Bordeaux University, Talence, France.

C Serdjebi (C)

SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.

A Boyer (A)

SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.
Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.

P Tomasini (P)

Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.

C Pouypoudat (C)

Radiation oncology department, Haut-Lévêque Hospital, Pessac, France.

D Barbolosi (D)

SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.

F Barlesi (F)

SMARTc Unit, Center for Research on Cancer of Marseille (CRCM), Inserm UMR 1068, CNRS UMR 7258, Aix-Marseille University U105, Marseille, France.
Multidisciplinary Oncology and Therapeutic Innovations Department and CRCM, Inserm UMR 1068, CNRS UMR 7258, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, Marseille, France.

F Chomy (F)

Clinical oncology department, Institut Bergonié, Bordeaux, France.

S Benzekry (S)

MONC team, Inria Bordeaux Sud-Ouest, Talence, France. sebastien.benzekry@inria.fr.
Institut de Mathématiques de Bordeaux, Bordeaux University, Talence, France. sebastien.benzekry@inria.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH